Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | NNMT | P40261 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106649 | 0.89 | MAPKAPK2 (0.32) | SIRT6ALDH1A1 | |
| SCHEMBL13114213 | 0.80 | SIRT6 (0.39) | SIRT6FGFR1NNMTLMNADHFR | |
| SCHEMBL274632 | 0.77 | — | — | |
| SCHEMBL29457483 | 0.77 | — | — | |
| SCHEMBL11227327 | 0.77 | NNMT (0.35) | SIRT6HTTCHRNB2CHRNA4NNMT | |
| SCHEMBL31022760 | 0.77 | POLB (0.36) | SIRT6HTTKMT2ACHRNB2CHRNA4 | |
| SCHEMBL28190092 | 0.77 | MAPT (0.38) | SIRT6HTTFGFR1NNMTLMNA | |
| SCHEMBL10314188 | 0.77 | SIRT6 (0.37) | SIRT6FGFR1NNMTLMNADHFR | |
| SCHEMBL13500438 | 0.77 | POLB (0.36) | SIRT6HTTKMT2ACHRNB2CHRNA4 | |
| SCHEMBL4136927 | 0.75 | SIRT6 (0.36) | SIRT6FGFR1NNMTLMNAP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110275661-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110275661-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110275661-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED | 2011-11-10 | — | — | US | disclosed |
| WO-2011081310-A3 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME | 한국기초과학지원연구원 (KR) | 2011-10-27 | — | — | WO | disclosed |
| EP-2352734-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010043714-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043714-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | disclosed |
| EP-1458715-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003051870-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | SIRT6 1464/4885HTT 4258/4885KMT2A 4349/4885 |
| US-20110275661-A1 | TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS | NRDC, NGLY1, NISCH | SIRT6 2561/4885HTT 2507/4885KMT2A 4325/4885 |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | CCL11, CCL2, CCR2 | SIRT6 1464/4885HTT 4258/4885KMT2A 4349/4885 |
| US-20050075346-A1 | Novel compounds | CCL11, CCL2, CCL5 | SIRT6 1455/4885HTT 4728/4885KMT2A 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.